ArticleCancer management and research2025
Tumor-Associated Autoantibodies Anti-p53 is Associated with Poor Prognosis in Patients with Lung Adenocarcinoma.
Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: There is a known association between tumor-associated autoantibodies (TAAbs) and lung cancer. TAAbs are currently used in clinical settings for the early detection of lung cancer. However, the relationship between TAAbs profiles and clinical outcomes in lung cancer patients remains incompletely understood. This study aims to investigate the association between TAAbs and survival rates in individuals diagnosed with lung adenocarcinoma. Patients and Methods: This study enrolled 161 patients diagnosed with lung adenocarcinoma at Henan Province People's Hospital between January 2020 and December 2022. Levels of TAAbs were measured using a commercial enzyme-linked immunosorbent assay (ELISA) kit. Follow-up data were collected through December 2024. The association between TAAbs levels and disease progression was evaluated using Kaplan-Meier survival analysis and Cox proportional hazards models. Results: In the univariate analysis, the presence of p53 autoantibodies (anti-p53) and CAGE autoantibodies (anti-CAGE) was associated with an increased risk of reduced progression-free survival (PFS). In the multivariate analysis, anti-p53 remained significantly associated with shorter PFS, while anti-CAGE was not correlated with poor prognosis. The significant association between anti-p53 and worse PFS persisted after adjusting for gender, age, smoking status, pathological stage, and treatment. Kaplan-Meier survival analysis further confirmed that patients positive for anti-p53 had significantly shorter PFS ( Conclusion: Tumor-associated autoantibody anti-p53 correlates poor prognosis in lung adenocarcinoma patients, offering novel insights into tumor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.